Clinical-grade CAR-T cell manufacturing was performed in a closed system using a second-generation CD19 vector with 41BB costimulatory ... by quantitative PCR with the MACS Copycheck Kit human ...

German biotechnology company Miltenyi Biotec has said that its CAR-T therapy ... The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.

German biotechnology company Miltenyi Biotec has said that its CAR-T therapy ... The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.